Basit öğe kaydını göster

dc.contributor.authorOflaz, Mehmet Burhan
dc.contributor.authorBallı, Şevket
dc.contributor.authorKibar, Ayşe Esin
dc.contributor.authorEce, İbrahim
dc.contributor.authorAkdeniz, Celal
dc.contributor.authorTuzcu, Volkan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:53Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:53Z
dc.date.issued2013en_US
dc.identifier.citationOflaz, M. B., Ballı, Ş., Kibar, A. E., Ece, İ., Akdeniz, C. ve Tuzcu, V. (2013). Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy. Medical Science Monitor, 19(1), 366-372. https://dx.doi.org/10.12659/MSM.883911en_US
dc.identifier.issn1234-1010
dc.identifier.urihttps://hdl.handle.net/20.500.12511/979
dc.identifier.urihttps://dx.doi.org/10.12659/MSM.883911
dc.description.abstractThe purpose of this study was to examine the effects of carvedilol therapy on autonomic control of the heart and QT-interval dispersion (QTd) among children with idiopathic dilated cardiomyopathy (DCM) whose symptoms were not adequately controlled with standard congestive heart failure therapy. Material/Methods: Patients with DCM who were treated with carvedilol were enrolled in the study. All patients had undergone carvedilol therapy in addition to standard therapy for at least 6 months. Clinical, echocardiographic, and electrocardiographic parameters, and 24-h Holter records of patients were retrospectively evaluated before and after carvedilol treatment. Results: A total 34 patients (mean age: 7.4±4.3 years) with DCM were analyzed in the study. The median follow-up period was 9.5 months. After the 6 months of carvedilol therapy the clinical score significantly improved, left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) significantly increased, and left ventricle enddiastolic dimensions and end-systolic dimensions significantly decreased. There were statistically significant increases in mean SDNN, SDANN, rMSSD, and pNN50 (p=0.002, p=0.001, p=0.008, and p=0.026, respectively). After the carvedilol therapy, SDNN was correlated with the clinical score, heart rate, LVEF, LVFS, and total premature ventricular contractions (PVCs). In addition, rMSSD and pNN50 were correlated with heart rate, LVEF and LVFS. A significant reduction was observed in QTc-minimum, QTc-maximum, and QTd values (434.9±40.7 vs. 416.1±36.5, 497.8±43.6 vs. 456.3±41.7, 58.6±17.1 vs. 49.3±15.6; p<0.001, p=0.001, and p=0.008, respectively). QTd was significantly related to PVCs (r=0.62, p=0.02). Conclusions: We conclude that the addition of carvedilol to standard therapy can improve clinical symptoms and heart rate variability, and reduce in arrhythmia markers in children with DCM.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCarvedilolen_US
dc.subjectChildrenen_US
dc.subjectDilated Cardiomyopathyen_US
dc.subjectHeart Rate Variabilityen_US
dc.subjectQT Dispersionen_US
dc.titleEffects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathyen_US
dc.typearticleen_US
dc.relation.ispartofMedical Science Monitoren_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-8647-6055en_US
dc.authorid0000-0001-9008-4997en_US
dc.identifier.volume19en_US
dc.identifier.issue1en_US
dc.identifier.startpage366en_US
dc.identifier.endpage372en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.12659/MSM.883911en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster